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Despite advances in combinatorial chemotherapy regimens and the advent of intraperitoneal chemotherapy
administration, current therapeutic options for ovarian cancer patients are inadequate. Immunotherapy offers a
novel and promising therapeutic strategy for treating ovarian tumors. Following the demonstration of the
immunogenicity of ovarian tumors, multiple immunotherapeutic modalities have been developed. Antibody-based
therapies, immune checkpoint blockade, cancer vaccines, and chimeric antigen receptor-modified T cells have
demonstrated preclinical success and entered clinical testing. In this review, we discuss these promising
immunotherapeutic approaches and emphasize the importance of combinatorial treatment strategies and
biomarker discovery.
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In 2012, there were an estimated 239,000 new cases of
ovarian cancer worldwide leading to over 140,000 deaths
[1]. Epithelial ovarian cancer is the fourth most common
cause of cancer-related death in women in the developed
world, where it is also the leading cause of death from
gynecological malignancies [2]. The lethality of ovarian
cancer is in part due to the difficulty of early detection.
Ovarian cancer causes few perceptible symptoms when
localized to the ovary. Due to the asymptomatic nature
of early disease, most patients do not seek medical care
until the disease has progressed beyond the ovaries into
the abdomen and pelvis [3]. Nearly 75% of patients present
with stage III and IV ovarian cancer [4]. Management of
ovarian cancer primarily includes cytoreductive surgery
and platinum-based chemotherapy. While clinical remis-
sions are obtainable, the majority of patients will relapse
and die of disease, with a 5-year survival of approximately
30% [5]. Novel therapies need to be integrated into ovar-
ian cancer treatment strategies to achieve durable clinical
outcomes.
In the last two decades, advances in the understanding
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treatment. A crucial early step in establishing the validity
of ovarian cancer immunotherapy was the observation
that CD3+ tumor-infiltrating T cells correlated with in-
creased overall survival [6]. Later work confirmed the
importance of tumor-infiltrating lymphocytes (TILs) and
specifically identified the CD3+, CD8+ T cells as import-
ant antitumor effectors [7]. The identification of tumor-
associated antigens (TAAs) lent additional support to an
immunotherapeutic treatment strategy. TAAs aberrantly
up-regulate in tumor tissue and ascites of ovarian cancer
patients and include members of the cancer-testis antigen
family (e.g. MAGE-A4 and NY-ESO-1), growth-activating
receptors (e.g. HER2/neu), folate receptor alpha (FRα),
p53, and CA125 [8-10]. These markers are potential
therapeutic targets for eliciting an immune response
specific to ovarian cancer and effecting immune-mediated
tumor rejection. The Food and Drug Administration
(FDA) has approved immunotherapies for prostate cancer,
advanced kidney cancer, lymphoma, and metastatic
melanoma, but only recently have immunotherapies tar-
geting ovarian cancer entered clinical testing (Table 1). In
this review, we discuss advances in immunotherapeutic
approaches to ovarian cancer. We divide therapeutic strat-
egies into four categories: antibodies, immune checkpoint
inhibitors, vaccines, and adoptive cell therapy (ACT).his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Key trials in ovarian cancer immunotherapy








Interleukin-2 i.p. 24 CR: 4 Median Survival:
6 × 105 IU/ml weekly × 16 PR: 2 Non-Responder:
SD: 7 1.5 years
Responders: not reached
(24 -120+ months)
Hodi, Dranoff Recurrent metastatic ovarian
cancer
CTLA-4 Blockade: 9 CR: 0 Duration of Response:
PNAS 2008 Ipilupimab i.v. 3 mg/kg q 2 – 3 months PR: 1 SD: 2,4,6+ Months
SD: 3 PR: 35+ Months
Diefenbach, Dupont “High Risk” ovarian cancer after
surgery and 1st line chemo
NY-ESO-1b peptide (position 157–165;
100 μg) + 0.5 mL Montanide ISA-51
s.c. q 3 weeks × 5
9 NA Median PFS: 13 months
Clin Cancer Res 2008 6/9 patients recurred
3 patient disease free
after 25, 38, and 52
Fujita,Tanaka Clin
Cancer Research 1995
NED after surgery and 1st line
chemo
1.0 – 4.4 × 109 TIL after 1st line chemo 13 TIL NA 3-year DFS:






Chu, June Consolidation after 1st line
treatment or secondary debulking
Her-2/neu, hTERT, PADRE-loaded
Dendritic cells +/− Cyclophosphamide






Odunsi, Jaeger Consolidation after 1st line
treatment
I.d. rV-NY-ESO-1, 22 NA PFS: 21 months
PNAS 2012 3.1 × 107 PFU, monthly s.c. OS: 48 months
rF-NY-ESO-1, 7.41 × 107 PFU for 6 mo.
Rahma, Khleif HLA-A2.1 + stage III, IV,
or recurrent ovarian
Arm A: s.c. wt p53:264–272 peptide
with Montanide and GM-CSF.







p53 protein, no evidence of
disease
Arm B: i.v. wt p53:264–272
peptide-pulsed dendritic cells IV
OS: 40.8 months





Adapted from: Kandalaft LE, Powell DJ Jr, Singh N, Coukos G. Immunotherapy for ovarian cancer: what’s next? J Clin Oncol. 2011 Mar 1;29(7):925–33.
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In the last fifteen years, antibody-based therapies for
hematologic cancers and solid tumors have become well-
established therapeutic strategies. Following rituximab’s
1997 FDA-approval for treating chemotherapy-resistant
non-Hodgkin lymphomas, 18 other molecular antibodies
have gained FDA approval for use in oncologic care. Anti-
body therapy is a promising area of research and increas-
ingly antibody therapies are being used in ovarian cancers.Bevacizumab
Bevacizumab (Avastin®, Roche) is a humanized monoclo-
nal antibody (mAb) that binds to all isoforms of the vas-
cular endothelial growth factor (VEGF) receptor ligand.
VEGF is a key mediator of developmental angiogenesis
and has been shown to regulate the vascularization of
tumors [11]. Anti-VEGF antibody therapy has proven
effective in multiple cancer subtypes including meta-
static colorectal cancer, glioblastoma, non-small cell lung
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ing candidate for VEGF therapy; in biopsies from ovarian
tumors, VEGF gene expression correlates with a poor
prognosis [13]. The results of the phase III AURELIA trial
show that the addition of bevacizumab to single-agent
chemotherapy leads to increased progression-free survival
(PFS) and overall response rate (ORR): PFS increased from
3.4 months to 6.7 months and ORR increased from 11%
to 27% [14].
Catumaxomab
Catumaxomab (Removab®, Fresenius Biotech GmbH) is
a bispecific, trifunctional antibody directed against the
epithelial cell adhesion molecule (EpCAM) and the T
cell antigen CD3. Primary, metastatic, and recurrent epi-
thelial ovarian cancers express EpCAM at a significantly
elevated level compared to normal human surface epi-
thelium [15]. Catumaxomab uses the EpCAM and CD3
binding domains to recruit and activate immune effector
cells at the tumor site [16]. Antitumor effects are exerted
via two complementary pathways. First, the bispecific
structure of the antibody facilitates T cell-mediated cyto-
toxicity by localizing the T cell and tumor tissue. Simul-
taneously, the retention of a functional Fc domain on the
bispecific antibody allows natural killer (NK) cells to lyse
tumor via antibody-dependent, cell-mediated cytotoxicity
[17,18]. In a randomized Phase II/III study including 129
patients, puncture-free survival was significantly longer in
the group receiving catumaxomab [19]. Recently, a Phase II
study of catumaxomab in chemotherapy-refractory ovarian
cancer patient with malignant ascites demonstrated a bene-
fit for catumaxomab therapy: catumaxomab prolonged
both the puncture free interval and the time to first thera-
peutic puncture as well as producing improvement in
quality of life [20].
Cetuximab and panitumumab
Cetuximab (Erbitux®, BMS and Eli Lilly) is a chimeric,
IgG1, mAb that binds to the extracellular domain of the
epidermal growth factor receptor (EGFR) preventing
EGFR-signaling and accelerating receptor internalization
[21]. Cetuximab is routinely administered in the treatment
of metastatic colorectal cancer and metastatic head and
neck cancer. Up to 70% of ovarian cancer tumors and all
histologic subtypes of ovarian cancer are EGFR-positive,
making EGFR a promising therapeutic target in ovarian
cancer [22]. In vitro, treating ovarian cancer cell lines with
cetuximab inhibits cell growth, potentiates apoptosis, and
impairs tumor metastasis [23].
A phase II trial of single-agent cetuximab in persistent/
recurrent ovarian or primary peritoneal carcinoma found
minimal clinical benefit: nine patients had stable disease,
while only one of 25 patients achieved a partial response
[24]. However, a phase II trial testing cetuximab incombination with carboplatin in platinum-sensitive ovar-
ian cancer patients reported encouraging results [25]. Out
of 29 patients, 9 demonstrated an objective response and
8 had stable disease. Panitumumab (Vectibix®, Amgen) is
another anti-EGFR antibody with strong, early-phase
clinical data. A phase II study of panitumumab and the
chemotherapeutic pegylated liposomal doxorubicin (PLD)
in platinum-resistant ovarian cancer reported a 9% partial
response rate with stable disease in 19% of patients [26].
Out of the 32 evaluable patients, 24% had decreased levels
of CA125, a surrogate marker for ovarian tumor burden.
The limitations of single-agent cetuximab, but success
of anti-EGFR therapy in combination with chemothera-
peutics highlights an important preclinical reality in im-
munotherapy: chemotherapy and immunotherapeutics
can act synergistically to enhance antitumor immunity
and improve therapeutic outcomes. Chemotherapy has
historically been thought to be immunosuppressive, but
recent work suggests the opposite. In a variety of tumor
types, patients with greater numbers of TILs have a bet-
ter clinical response to cytotoxic chemotherapy [27,28].
Oxaliplatin and cisplatin, common chemotherapies for
ovarian cancer, have been shown to increase dendritic
cells ability to induce antigen-specific T cell proliferation
[29]. In ID8 murine ovarian cancer cells, the combination
of chemotherapeutic PLD and the immunotherapy Inter-
leukin 18 (IL-18) resulted in enhanced tumor suppression
relative to either agent as a monotherapy [30]. In EGFR-
expressing xenograft models, the efficacy of cetuximab
can be increased by different classes of chemotherapeutic
agents, including cisplatin, doxorubicin, paclitaxel and
topotecan [31,32]. In the future, strategic implementation
of chemotherapy-immunotherapeutic combinations could
significantly improve ovarian cancer outcomes.
TAM-targeting antibodies
Tumor-associated macrophages (TAMs) are a major stro-
mal component in solid tumors. In the ovarian tumor
microenvironment, TAMs are the most abundant subset
of infiltrating immune cells [33]. However, macrophages
are commonly classified into two subsets with different
cytokine profiles, surface phenotypes, and functional
effects on tumor growth [34]. Classical (M1-polarized)
macrophages are activated by interferon-γ (IFN-γ) and
characterized by the production of proinflammatory and
immunostimulatory cytokines (e.g. IL-6, IL-12). M1 mac-
rophages express high levels of major histocompatibility
complex (MHC) I and II and thus play a critical role in
tumor antigen presentation. Through immune system
stimulation and antigen presentation, M1 macrophages
have a net tumoricidal effect. Alternative (M2-polarized)
macrophages are activated by Th2 cytokines (e.g. IL-4,
IL-10) and exert anti-inflammatory effects. Recent work
reports a correlation between improved 5-year prognosis
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In ovarian tumors, M2 macrophages contribute to mul-
tiple mechanisms of TAM-mediated immunosuppression.
Ovarian tumor macrophages upregulate and secrete the
chemokine CCL22 which promotes T regulatory cell (Treg)
trafficking to the tumor. In mice bearing primary human
ovarian tumors, treatment with an anti-CCL22 mAb
decreased Treg migration into tumors [36]. In addition to
CCL22 expression, ovarian tumor macrophages express
another receptor with immunosuppressive properties,
B7-H4. B7-H4 is a member of the B7 family of T
cell-antigen presenting cell (APC) regulatory molecules.
In ovarian cancer patients, >70% of freshly isolated tumor
macrophages expressed B7-H4 and in vitro B7-H4+ mac-
rophages significantly decrease T cell proliferation and T
cell activation upon TAA recognition [37]. Treatment of
B7-H4+ TAMs with single chain fragments of antibody
variable regions (scFvs) that target and block B7-H4, can
reverse tumor immunosuppression and induce T cell
activation [38].
While anti-CCL22 mAbs and anti-B7-H4 scFvs exert
antitumor effects by modulating macrophage-T cell
interactions, targeting the macrophage colony stimulating
factor-1 receptor (CSF-1R) directly depletes immunosup-
pressive TAMs. Colony stimulating factor, also known as
macrophage colony stimulating factor (CSF-1 or M-CSF),
regulates the migration, proliferation, survival, and function
of macrophages [39]. Macrophages rely on pro-growth,
M-CSF signaling for survival and blocking CSF-1R pro-
vides an avenue for decreasing M2-polarized TAMs. In
murine tumor models with high TAM-infiltration, the
administration of an anti-CSF-1R mAb significantly
reduced TAMs and simultaneously increased the ratio of
cytotoxic CD8+ T cells to CD4+ T cells while decreasing
the number of FoxP3+ Tregs [40]. In 2011, a humanized
anti-CSF-1R mAb, RG7155 (Roche), entered clinical trials.
The results from the ongoing Phase Ia/Ib clinical trial
(NCT01494688) indicate that RG7155 treatment is well
tolerated and effectively depletes TAMs [41]. Targeting
macrophages is a promising therapeutic approach to
ovarian cancer and encouraging early work indicates
that CSF-1R blockade, anti-B7-H4 scFvs, and anti-CCL22
mAbs may generate potent antitumor responses.
Immune checkpoint inhibitors
Immune checkpoints are inhibitory pathways that down-
regulate activated T cells following antigen presentation
and costimulatory signaling by APCs. By controlling the
intensity and duration of the immune response, immune
checkpoint signaling prevents collateral self-tissue dam-
age. During tumorigenesis, however, cancer cells express
proteins that activate immune checkpoint pathways and
induce immune suppression thereby evading targetingand removal by the immune system. The clinical successes
of antibodies modulating immune checkpoints continue
to fuel the enthusiasm surrounding immunotherapeutic
approaches to cancer treatment.
CTLA-4
The cytotoxic T-lymphocyte-associated protein 4 (CTLA-4
or CD152) plays a vital role in regulating T-cell activation
[42]. Activation is triggered through antigen recognition by
the T-cell receptor (TCR), but costimulatory and coinhibi-
tory signaling dictates the magnitude of the resulting
response. The cell surface molecule CD28 and its ligands
CD80 (B7-1) and CD86 (B7-2) are the primary source of
costimulatory signaling [43]. CD80 and CD86 are pre-
dominantly found on antigen-presenting cells like mono-
cytes, activated B cells, and dendritic cells [44]. However,
CD80 and CD86 do not exclusively induce activating sig-
nals, they are also the ligands of CTLA-4, a key negative
regulator of T cell activation [45]. CTLA-4 directly com-
petes with CD28 for binding to CD80 and CD86. CTLA-4
ligation results in the termination of T cell activation, cell
cycle arrest, and T cell anergy. By limiting or reversing T
cell activation, CTLA-4 serves as an important immune
checkpoint that helps contain immune responses.
In the immunosuppressive tumor microenvironment,
blocking CTLA-4 has the potential to directly activate
CD4+ and CD8+ effector T cells, leading to tumor clear-
ance. In a variety of preclinical tumor models, the
administration of an antagonistic anti-CTLA-4 antibody
induced tumor rejection [46]. The successes of anti-
CTLA-4 therapy revitalized interest in the field of
immunotherapy and resulted in the 2011 FDA approval
of the anti-CTLA-4 mAb ipilimumab (Yervoy®, Bristol-
Myers, Squibb) [47]. The majority of clinical experience
with ipilimumab has come from studies in patients with
melanoma, but a Phase II study of ipilimumab mono-
therapy in patients with platinum-sensitive ovarian can-
cer is ongoing (NCT01611558).
PD-1 and PD-L1 axis
The programmed cell death protein-1 (PD1) and its ligand
(PD-L1) represent a promising immune checkpoint
pathway that can be targeted to reverse tumor-mediated
immunosuppression. Ligation of PD1 suppresses the lytic
activity of immune effector subsets [48]. In ovarian cancer,
PD-L1 expression on monocytes in the ascites and blood
of patients with malignant cancer correlates with poor
clinical outcome [49]. Cytotoxicity assays revealed that
PD-L1 overexpression on murine ovarian cancer ID8 cells
inhibited cytotoxic T lymphocyte (CTL) degranulation
and reduced CTL-mediated tumor lysis; PD-L1 blockade
reversed this effect. Recently, results were presented from
a phase I trial of the anti-PD1 mAb, nivolumab (BMS), in
patients with platinum-resistant ovarian cancer [50]. Out
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partial responses and 26% had stable disease. The valid-
ation of antibodies targeting the PD-1/PD-L1 axis arrived
in late 2014 when the FDA granted accelerated approval
to pembrolizumab (Keytruda, Merck). Pembrolizumab
is an anti-PD1 mAb that achieved an ORR of 26% in
ipilimumab-refractory advanced melanoma patients [51].
mAbs targeting PD1 and PD-L1 are currently being evalu-
ated in over 100 clinical trials and ovarian cancer remains
a prioritized indication for testing.
IDO
In addition to transmembrane receptor targets, meta-
bolic enzymes are being investigated as therapeutic strat-
egies for reversing immunosuppression within the tumor
microenvironment. Indoleamine 2,3-dioxygenase (IDO)
is the leading metabolic immune regulator in clinical
development.
IDO is an intracellular enzyme that catalyzes the initial
and rate-limiting step of the oxidative catabolism of the
amino acid tryptophan [52]. Tryptophan catabolism is
believed to influence immunodynamics via two mecha-
nisms: tryptophan depletion starves T lymphocytes trig-
gering cell cycle arrest and apoptosis and the tryptophan
metabolite kynurenine is toxic to lymphocytes [53,54].
Kynurenine accumulation has been linked to the selective
apoptosis of T cells, monocytes, and macrophages [55,56].
Kynurenine can also induce the expansion of Tregs.
Plasmacytoid dendritic cells (pDCs) with elevated levels of
IDO can convert naive CD4+ T cells into Treg cells [57].
Inhibiting IDO in pDCs abrogates Treg generation, but
adding kynurenine restores the conversion of CD4+CD25− T
cells into Tregs. With mounting evidence for the im-
munosuppressive effects of IDO, its role in tumor im-
mune evasion is increasingly under investigation.
The role of IDO in human cancer was first docu-
mented in 2003 by Uyttenhove et al. who reported con-
stitutive IDO expression in most human tumors and
linked elevated IDO levels to a low frequency of TILs in
murine cancer models [58]. In ovarian cancers, immuno-
histochemical scoring of IDO expression in surgically
resected tissue has demonstrated that IDO is prevalent
in ~56% of ovarian tumors and correlates with a reduced
number of CD8+ TILs [59]. IDO expression also inhibits
NK cell accumulation in ovarian tumors and promotes
tumor angiogenesis [60]. In patients with serous-type
ovarian cancer, increased synthesis of IDO is positively
associated with impaired survival, but this trend was not
true for other histological subtypes of OC [61]. Gene
expression profiling has also found elevated IDO levels
in paclitaxel-resistant ovarian cancer tissues [62].
The first IDO-targeted therapy to enter preclinical test-
ing was 1-methyl-tryptophan (1-MT), a small molecule in-
hibitor of IDO. In an IDO-overexpressing ovarian cancermodel, combination treatment of paclitaxel and 1-MT
synergistically prolonged mouse survival relative to pacli-
taxel monotherapy [59]. This result supports earlier work
that suggests IDO-inhibition augments the efficacy of
cytotoxic chemotherapeutic agents and IDO-based com-
bination therapy may eradicate tumors that are refractory
to single-agent therapy [63]. 1-MT treatment also signifi-
cantly suppressed tumor dissemination and ascites after
IDO-overexpressing ovarian cancer cells were implanted
into syngeneic immunocompetent mice [64].
Currently, the IDO inhibitor Indoximod® (NewLink
Genetics) is in five clinical trials with encouraging early-
phase clinical data [65]. In a phase I trial of Indoximod
in combination with docetaxel in patients with meta-
static solid tumors 18% of treated patients exhibited a
partial response and 41% had stable disease. In a phase
IB/II trial of indoximod in combination with AD.p53DC,
a dendritic cell cancer vaccine, 9% of patients achieved
stable disease with initial treatment. Following combin-
ation therapy, 11 patients showed tumor progression and
then received gemcitabine-based chemotherapy; 54% of
these patients achieved an objective response. A second-
generation IDO-inhibitor, NLG919 (NewLink Genetics),
entered clinical trials in late 2013 (NCT02048709). Both
inhibitors are orally bioavailable and are being tested in
patients with recurrent solid tumors.
In addition to the IDO inhibitors developed by NewLink
Genetics, INCB024360 (Incyte Corp.), an IDO1 inhibi-
tor, has entered clinical testing. In preclinical data,
INCB024360 was shown to significantly inhibit tumor
growth and to induce T and NK cell proliferation and
IFN-γ production [66]. In the Phase I safety and tolerabil-
ity trial, at doses above 300 mg twice a day, 90% inhibition
of IDO activity was observed, with pneumonitis and
fatigue reported as the only dose-limiting toxicities [67]. A
Phase II trial of INCB024360 monotherapy versus tamoxi-
fen in patients with epithelial ovarian cancer is ongoing
(NCT01685255). As IDO inhibitors enter the clinic, it will
be important to monitor the immunologic effects of global
IDO inhibition with special attention focused on the onset
of autoimmune dysfunction. In the MRL-lpr mouse model
of spontaneous lupus disease, 1-MT treatment accelerates
lupus onset [68].
Vaccine strategies
Therapeutic cancer vaccines have been an area of research
interest since the 1920s, when injections of lymph node
extracts were used to treat Hodgkin’s lymphoma. The
promise of vaccine strategies is the potential to “teach”
individual patients’ immune systems to recognize, target,
and eradicate tumor cells in an approach that employs
both adaptive and innate immunity. Vaccines aim to pro-
voke a tumor-specific immune response by increasing
TAA presentation by APCs thus generating tumor-antigen
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surgery, radiotherapy, or antibody therapy, an effective
vaccine-induced immune response could establish a state
of immunological memory that persists after tumor
clearance and indefinitely suppresses tumor regrowth. In
recent decades, multiple approaches to therapeutic cancer
vaccines have been developed and dendritic cell vaccines
have emerged as efficacious in ovarian cancer.
Ex vivo DC vaccines
Dendritic cells (DCs), the most potent class of APCs, are
responsible for processing cancer antigens from tumor
cells and presenting peptide fragments to naive T cells, B
cells, and NK cells. DC vaccines attempt to enhance DC
uptake and presentation of TAAs, galvanizing an antitu-
mor response. In ovarian cancer, a promising TAA for
DC vaccines is mucin 1 (MUC-1). MUC-1 is a heavily gly-
cosylated, type 1 transmembrane protein that is overex-
pressed in a large number of cancers including colorectal,
pancreatic, and ovarian [69]. While multiple MUC-1 vac-
cines are now in development, CVac® (Prima BioMed) is
the leading candidate for treatment of ovarian cancer.
CVac is produced by culturing isolated DCs ex vivo with
MUC-1. In the CAN-003 Phase II study, 63 epithelial
ovarian cancer patients in complete remission received
CVac. In the patients who had achieved a remission after
second-line therapy, PFS and OS were increased [70].
In vivo DC vaccines
Ex vivo DC vaccines require isolating and stimulating
DCs on a patient-specific basis and are thus costly,
labor-intensive, and mostly limited to large, academic
medical centers. An attractive alternative is to use an
“off-the-shelf” therapeutic that is not patient-specific and
stimulates DCs to uptake TAAs in vivo. One example of
an early, preclinical success with this approach in ovar-
ian cancer is the administration of a vaccine based on
the MSLN-Hsp70 fusion protein [71]. The MSLN-Hsp70
protein combines a scFv to mesothelin (MSLN), an anti-
gen overexpressed in pancreatic and ovarian tumors,
and a heat shock protein from Mycobacterium tubercu-
losis (Hsp70). In this system, the dendritic cells are acti-
vated by the tuberculosis Hsp70 and, because the fusion
protein localizes DC activation to MSLN-expressing cells,
immediately recognize the tumor antigen. Administration
of the bifunctional fusion protein in mouse models of
ovarian cancer significantly enhanced survival and slowed
tumor growth while augmenting tumor-specific CD8+ T
cell responses.
Whole tumor DC-based vaccines
A potential avenue for improving the efficacy of DC vac-
cines is the inclusion of multiple tumor antigens during
DC priming. When immunotherapeutic intervention islimited to a single target antigen, there is the possibility
of tumor escape. Tumor escape occurs when the tumor
mutates to downregulate the immunogenic antigen and
thus evades immune system surveillance and continues
to proliferate. By preparing vaccines from whole tumor
cells, the immune system can be trained to recognize a
broad range of TAAs. Whole-tumor preparations also
eliminate the need for researchers to identify an optimal
antigen target; unknown tumor antigens may drive or
contribute to the cellular immune response. Recent work
utilized a lysate of tumor cells to demonstrate the effect-
iveness of whole tumor DC-based vaccination against
ovarian cancer in both a preclinical and clinical setting
[72]. In the clinic, out of the five patients who received
the DC vaccine, two had PFS of 24 months or more
(NCT01132014).
Peptide vaccines
Peptide vaccines rely primarily on the immunogenicity of
the injected peptides to stimulate an immune response. In
the cancer setting, the peptides chosen for the vaccine are
TAAs. Recently, overlapping long peptides (OLP) from
NY-ESO-1 were used as a peptide vaccine in combination
with two different adjuvant preparations: Montanide and
Poly-ICLC [73]. After OLP vaccination alone, NY-ESO-1-
specific CD8+ T cells and NY-ESO-1-specific antibody
responses were undetectable, but after vaccination with
OLP and administration of both Montanide and Poly-
ICLC, 91% of patients demonstrated both a NY-ESO-1-
specific CD8+ T cells and a NY-ESO-1-specific antibody
response. Additional targets for peptide vaccine strategies
in ovarian cancer include p53, Her-2/neu, and CA125
[74-76]. While peptide vaccines have proven effective at
eliciting TAA-specific immune responses, combination
with complementary immunotherapeutic modalities may
be necessary to generate potent antitumor immunity.
Recombinant viral vaccines
Recombinant viral vaccines utilize genetically modified
viruses as vectors for introducing TAA-encoding DNA
into cells within the body [77]. Viruses are an attractive
antigen-delivery system because most viruses elicit an
immune response; viral immunogenicity induces immune
cell trafficking to the injection site, where professional
APCs, like DCs, encounter the newly introduced TAAs.
APCs then return to lymph nodes with the digested and
expressed TAA and induce a tumor-specific humoral or
cellular immune response. The discovery of TAAs for
ovarian tumors has spurred the development of thera-
peutic recombinant viral vaccines for patients with ovarian
cancer.
The cancer testis antigen NY-ESO-1 is a well-documented
target for immunotherapy of ovarian cancer and has been
the focus of multiple cancer vaccine studies [78-80].
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vectors were used in parallel Phase II clinical trials, produ-
cing encouraging immunologic data [81]. Induction of a
NY-ESO-1-specific antibody response was observed in
42% of patients who were seronegative at the baseline
assessment. CD8+ T cell responses were induced in 32% of
patients (14% had a preexisting response), while CD4+ T
cell responses were induced in 22% of patients (68% had a
preexisting response). In the ovarian cancer patients, the
median PFS was 21 months and the median overall
survival (OS) was 48 months. Poxviral vectors are also the
basis for the PANVAC vaccine platform, which is actively
being tested in ovarian cancer patients (NCT00088413).
PANVAC is a cancer vaccine therapy that contains trans-
genes for the TAAs MUC-1 and carcinoembryonic antigen
(CEA) as well as transgenes for three human T cell costi-
mulatory molecules, collectively known as TRICOM
(B7-1, intracellular adhesion molecule-1 and leukocyte
function-associated antigen-3) [82]. In a pilot study of
PANVAC in 14 ovarian cancer patients, median time
to progression was 2 months and median OS was
15.0 months [83].
The convenience, low toxicity, and potential thera-
peutic activity of vaccine strategies make them an irre-
sistible target of future immunotherapeutic research. As
optimal vaccine platforms, antigen targets, and adjuvant
conditions are identified, vaccines will become an in-
creasingly valuable therapeutic option for treating ovar-
ian cancer.
Adoptive cell therapy
Adoptive Cell Therapy (ACT) is an immunotherapeutic
technique that uses autologous or allogeneic antitumor
lymphocytes to induce cancer regression. In autologous
ACT, lymphocytes are isolated via apheresis, cultured,
and assayed for tumor recognition. Highly reactive cul-
tures are expanded and reinfused into the cancer patient.
Lymphodepleting chemotherapy preceding infusion elimi-
nates immunosuppressive cells and supports the in vivo
survival and expansion of tumor-specific lymphocytes.
First described in 1988, ACT initially demonstrated strong
responses in melanoma, but has since been tested in other
tumor types including ovarian cancers [84,85]. A 1995
trial comparing the effect of adoptive cell therapy on
advanced-stage epithelial ovarian cancer found the 3-year
overall survival rates between the ACT group and the con-
trols, who did not receive ACT, to be 100% and 67.5%, re-
spectively [86]. However, ACT is limited by the availability
of tumor-specific lymphocytes. Recent advances in cellular
genetic engineering have addressed this limitation. Using
retro-viral vectors, antigen-specific T cell receptors are
transduced into normal peripheral blood lymphocytes
(PBLs) converting them into cells that accurately target
and lyse tumor [87]. The antigen-specific T cell receptors,or chimeric antigen receptors (CARs), are composed of
scFvs specific to the tumor antigen of interest and a T cell
signaling domain capable of inducing activation.
In the ID8 mouse model of ovarian cancer, T cells trans-
duced to express an NKG2D-based CAR demonstrated an
endogenous antitumor immunity and long-term, tumor-
free survival [88]. Surviving mice developed T cell memory
responses that were protective: 90% of mice rejected the
rechallenge with ID8 tumor cells. In a separate study,
treatment with chimeric-NKG2D T cells also increased
the number of host CD4+ and CD8+ T cells at the tumor
site and increased the number of antigen-specific host
CD4+ T cells in the tumor and draining lymph nodes [89].
With encouraging initial results of CAR-based therapy in
ovarian models, multiple ovarian-specific tumor antigens
are being used in CAR development and ACT strategies
are moving towards the clinic [90].
Combinatorial immunotherapy
While single-agent immunotherapies have produced prom-
ising clinical responses, unleashing the maximal antitumor
immune response is likely to require combinatorial thera-
peutic strategies [91]. As illustrated above, for a tumor to
uncontrollably proliferate and evade detection by the im-
mune system, multiple “tumor escape mechanisms” must
act concertedly [92]. By combining immunotherapies, dif-
ferent stages of tumor escape can be targeted, creating the
possibility of synergistic and additive effects between
agents [93]. Despite the novelty of immunotherapeutic
treatments in ovarian cancer, combination strategies are
an area of intense research and combinatorial trials have
entered the clinic.
The initial combination immunotherapies for ovarian
cancer patients were based on immune checkpoint block-
ade strategies. In the ID8-VEGF model of ovarian carcin-
oma, researchers observed that up to half of TILs were
double positive for both CTLA-4 and PD-1 and displayed
a decreased proliferation capacity and inability to produce
effector cytokines [94]. Co-administration of anti-PD-1
antibodies and anti-CTLA-4 antibodies reversed the TIL
dysfunction and induced tumor regression in 50% of the
mice relative to 25% with either agent as a monotherapy.
The addition of the GM-CSF gene vaccine, GVAX, to the
therapeutic regimen further increased tumor rejection
to 75% in the ID8-VEGF mice. The combination of anti-
CTLA-4 and GVAX has also been tested in eleven-patients
with metastatic ovarian carcinoma [95]. Three patients
achieved stable disease as measured by CA-125 levels and
one patient achieved an objective response by radiographic
criteria and maintained disease control over four years with
regular infusions of anti-CTLA-4 antibody. In addition to
preclinical research, the recent successes of trials evaluat-
ing nivolumab have spurred nivolumab-based combina-
tions, including a Phase I/II trial evaluating nivolumab
Chester et al. Journal for ImmunoTherapy of Cancer  (2015) 3:7 Page 8 of 10and the IDO inhibitor INCB24360 in patients with ovarian
neoplasms (NCT02327078).
Combination immunotherapy trials have also ex-
panded to include vaccine strategies, mAb therapy, and
ACT. In a trial for patients with recurrent ovarian cancer,
a DC-based autologous whole-tumor lysate vaccine was
tested in combination with the anti-angiogenic mAb beva-
cizumab (NCT01312376). Of the six patients who partici-
pated, four patients demonstrated a clinical benefit and an
increase in tumor-reactive T cells following vaccination;
tumor reactivity was quantified by measuring IFN-γ secre-
tion [96]. From these four patients, three patients with re-
sidual measurable disease advanced to a study where they
received adoptive transfer of autologous vaccine-primed,
CD3/CD28-co-stimulated T cells (NCT00603460). By the
end of study, one patient had achieved a complete response,
one patient had a partial response, and one patient had
progressive disease [96].
In the near future, the number of combination immuno-
therapy studies targeting ovarian cancer patients will
dramatically increase. However, the application of multiple
immunotherapies simultaneously requires careful consid-
erations. Primarily, with combination treatments there is a
potential for overlapping toxicities and elevated risk of
sequela due to immune system disinhibition. Effective
adverse-event management will be a crucial element of
successful combination immunotherapy. Secondly, there
is a need to optimize the timing of agent administration;
in some situations, sequential administration may prove
more advantageous than concurrent administration. If
immune-related toxicities can be controlled and ideal
dosing determined, combinatorial immunotherapy may
dramatically improve the clinical outcomes of ovarian
cancer patients.
Conclusions
Early clinical successes have validated immunotherapeu-
tic treatment strategies and immunotherapies hold im-
mense potential to improve outcomes for patients with
ovarian cancer. In future research, it will be important
to identify the dominant immunosuppressive pathways
within ovarian tumors. A better understanding of the
relevant immuno-oncologic pathways and their corre-
sponding biomarkers will allow patients to be optimally
matched with therapies. In conjunction with biomarker
research, combination strategies should continue to be
explored. Combination approaches are uniquely appeal-
ing because different classes of immunotherapies target
potentially synergistic stages of tumor immunity. Within
the tumor microenvironment, immunotherapies may
increase antigen release or antigen presentation, induce
cytotoxicity via effector immune subsets, or remove im-
munosuppression. Identifying the optimal combination
of drugs to provoke a concerted antitumor response willtranslate to substantial improvements in long-term clinical
benefit.
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